Hana Klamová

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán et al. · Blood · 2008 · 437 citations · Full text

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková et al. · Blood · 2013 · 162 citations · Full text

Expression patterns of microRNAs associated with CML phases and their disease related targets

Kateřina Machová Poláková, Tereza Lopotová, Hana Klamová et al. · Molecular Cancer · 2011 · 141 citations · Full text

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

Kateřina Machová Poláková, Vojtěch Kulvait, Adela Benesova et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 77 citations · Full text

Bioinformatics, Chronic Phase, Radiation Oncology +13